C-YDUCGenflow Biosciences
SIRT6 gene therapy, AAV delivery, longevity therapeutics
editinggene therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-YDUC
C-YDUCC-YDUCSIRT6 gene therapy, AAV delivery, longevity therapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Genflow Biosciences states that it believes aging is a process that can be medically targeted, with the goal of developing medicines that could halt, slow, or reverse aging in both dogs and humans.
SourceGenflow Biosciences presents ageing as a modifiable biological process rather than an unavoidable fatal outcome, arguing that there is no rationale for a limited lifespan and that ageing should be treated as a risk factor that can be managed. The company says it develops and commercializes therapeutics for dogs and humans intended to halt or slow ageing, with the broader aim of extending healthy lifespan while reducing healthcare costs and the emotional and societal burden of ageing populations.
SourceGenflow Bioscience presents itself as a London-based anti-ageing research company that believes health can be improved by developing medicines intended to potentially halt or slow the ageing process, with the broader goal of extending healthy human lifespan through science.
SourceGenflow Biosciences states that ageing itself can be directly targeted with novel therapeutics in order to halt or slow its progression, extend healthspan and lifespan, and improve quality of life. The company presents this as a way to reduce healthcare costs and lessen the emotional and social burdens of an ageing population, and it highlights gene-based intervention, including its lead candidate GF-1002, as a promising route for both human and canine longevity therapies.
Source